review article | Q7318358 |
scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1035427468 |
P356 | DOI | 10.1023/B:JOMG.0000048770.90334.3B |
P698 | PubMed publication ID | 15557796 |
P50 | author | Deborah Thompson | Q73218846 |
Douglas F. Easton | Q59812154 | ||
P2860 | cites work | Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome | Q22011001 |
Dominant Negative ATM Mutations in Breast Cancer Families | Q22066027 | ||
Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients | Q24170410 | ||
Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1 | Q24321914 | ||
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | Q24531993 | ||
Study of a single BRCA2 mutation with high carrier frequency in a small population | Q24680535 | ||
How many more breast cancer predisposition genes are there? | Q24800566 | ||
BRCA2 mutation carriers, reproductive factors and breast cancer risk | Q24803237 | ||
Molecular portraits of human breast tumours | Q28032461 | ||
Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland | Q28140600 | ||
BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease | Q64050126 | ||
Segregation and linkage analysis of nine Utah breast cancer pedigrees | Q67929669 | ||
Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group | Q67979093 | ||
Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer | Q70812480 | ||
Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage | Q71046679 | ||
Germline BRCA1 185delAG mutations in Jewish women with breast cancer | Q71107825 | ||
BRCA2 germline mutations in male breast cancer cases and breast cancer families | Q71167609 | ||
A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals | Q71400891 | ||
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene | Q71955901 | ||
Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study | Q73022855 | ||
Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: linkage analysis in German breast cancer families | Q73085107 | ||
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group | Q73108544 | ||
BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer | Q73109324 | ||
Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population | Q73139263 | ||
Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families | Q73259292 | ||
Genomic rearrangements account for more than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families | Q73282154 | ||
Familial invasive breast cancers: worse outcome related to BRCA1 mutations | Q73300388 | ||
Tumour biological features of BRCA1-induced breast and ovarian cancer | Q73347724 | ||
Risk models for familial ovarian and breast cancer | Q73371929 | ||
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium | Q73375647 | ||
Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland | Q73400704 | ||
Apparent human BRCA1 knockout caused by mispriming during polymerase chain reaction: implications for genetic testing | Q73704841 | ||
Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk | Q73806219 | ||
Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study | Q74157664 | ||
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers | Q74405501 | ||
Frequency of breast cancer attributable to BRCA1 in a population-based series of American women | Q74449603 | ||
A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers | Q74459364 | ||
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer | Q77845970 | ||
Variation in BRCA1 cancer risks by mutation position | Q77857319 | ||
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers | Q78198665 | ||
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer | Q95721725 | ||
Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22 | Q57903143 | ||
Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer | Q59238528 | ||
A human BRCA1 gene knockout | Q60074873 | ||
Differential Contributions ofBRCA1andBRCA2to Early-Onset Breast Cancer | Q61647812 | ||
Survival and tumor characteristics of German hereditary breast cancer patients | Q61970395 | ||
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 | Q28212276 | ||
BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history | Q28267644 | ||
Linkage of early-onset familial breast cancer to chromosome 17q21 | Q28268902 | ||
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers | Q28387138 | ||
Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation | Q28586360 | ||
Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes | Q28768485 | ||
Biallelic inactivation of BRCA2 in Fanconi anemia | Q29616130 | ||
Identification of the breast cancer susceptibility gene BRCA2 | Q29616290 | ||
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium | Q29619206 | ||
Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease | Q30665466 | ||
A systematic review of genetic polymorphisms and breast cancer risk. | Q33766628 | ||
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium | Q33894527 | ||
The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype | Q33904762 | ||
Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility | Q33904964 | ||
CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies | Q33910280 | ||
The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations | Q33946674 | ||
Variation in cancer risks, by mutation position, in BRCA2 mutation carriers | Q34044197 | ||
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes | Q34115258 | ||
BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer | Q34145544 | ||
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers | Q34162534 | ||
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer | Q34189009 | ||
Breast cancer, Cowden disease and PTEN-MATCHS syndrome | Q34344820 | ||
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene | Q34354479 | ||
ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer | Q34384444 | ||
A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes | Q34385903 | ||
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer | Q34385912 | ||
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat | Q34389571 | ||
Cancer risks in BRCA2 mutation carriers | Q34504452 | ||
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group | Q34512590 | ||
Cancer Incidence in BRCA1 mutation carriers | Q34527264 | ||
Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities | Q34732377 | ||
Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado | Q35184354 | ||
Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus | Q35209967 | ||
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. | Q35238410 | ||
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women | Q35238946 | ||
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. | Q35643852 | ||
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence | Q35644167 | ||
Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype | Q35881865 | ||
BRCA1 mutations in southern England | Q36292995 | ||
Germline BRCA2 mutations in men with breast cancer | Q36431527 | ||
Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women | Q36438908 | ||
P53 germline mutations in childhood cancers and cancer risk for carrier individuals | Q36621004 | ||
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers | Q36623059 | ||
The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel | Q36642159 | ||
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer | Q37218535 | ||
Heterozygous ATM mutations do not contribute to early onset of breast cancer | Q38348222 | ||
Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland | Q38492869 | ||
The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim | Q38892074 | ||
Cancer risks in A-T heterozygotes | Q40580171 | ||
Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations | Q41194578 | ||
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds | Q41226231 | ||
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer | Q42450903 | ||
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families | Q42691997 | ||
BRCA-associated breast cancer in young women | Q43459769 | ||
The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. | Q43754304 | ||
BRCA2 germline mutations in male breast cancer patients in the Polish population | Q43840341 | ||
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. | Q43974233 | ||
Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations | Q44023983 | ||
The APCI1307K allele and breast cancer risk | Q44930023 | ||
Polymorphisms associated with circulating sex hormone levels in postmenopausal women | Q44938215 | ||
A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability | Q45181384 | ||
Contributions of ATM mutations to familial breast and ovarian cancer. | Q46062845 | ||
BRCA2 mutation in Icelandic prostate cancer patients | Q47618092 | ||
Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys | Q47648595 | ||
Cancer mortality in relatives of women with breast cancer: the OPCS Study. Office of Population Censuses and Surveys | Q47648609 | ||
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations | Q47696751 | ||
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. | Q49231162 | ||
Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles? | Q51051999 | ||
High constant incidence in twins and other relatives of women with breast cancer. | Q53403578 | ||
Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. | Q53464409 | ||
p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition | Q55670947 | ||
Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of aBRCA1orBRCA2Mutation | Q57250729 | ||
Prediction of pathogenic mutations in patients with early-onset breast cancer by family history | Q57266776 | ||
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation | Q57266937 | ||
Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome | Q57266956 | ||
Genome-wide scanning for linkage in Finnish breast cancer families | Q57274804 | ||
High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients | Q57419184 | ||
Polyglutamine repeat length in theAIB1 gene modifies breast cancer susceptibility inBRCA1 carriers | Q57499707 | ||
The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators | Q57694684 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | breast cancer | Q128581 |
epidemiology | Q133805 | ||
P304 | page(s) | 221-236 | |
P577 | publication date | 2004-07-01 | |
P1433 | published in | Journal of Mammary Gland Biology and Neoplasia | Q15724460 |
P1476 | title | The genetic epidemiology of breast cancer genes | |
P478 | volume | 9 |
Q57138904 | Q57138904 |
Q42181679 | A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer |
Q37272982 | A genome wide linkage search for breast cancer susceptibility genes |
Q37024369 | A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protoc |
Q36614153 | ATM haplotypes and breast cancer risk in Jewish high-risk women |
Q37310896 | Acetylation Enhances the Promoting Role of AIB1 in Breast Cancer Cell Proliferation |
Q38777072 | Alcohol consumption and breast cancer risk by family history of breast cancer and folate intake in younger women |
Q33667724 | An investigation of breast cancer risk factors in Cyprus: a case control study |
Q93271377 | Association of DEAR1 Tagging Single Nucleotide Polymorphisms With Breast Cancer in a Sample of Colombian Population: A Case Control Study |
Q64948494 | BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance. |
Q64284450 | BRCA1 and Breast Cancer: a Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers |
Q49544412 | Biomarker Studies in Early Detection and Prognosis of Breast Cancer. |
Q51820568 | Bovine tuberculosis: the genetic basis of host susceptibility. |
Q37945448 | Breast cancer genome-wide association studies: there is strength in numbers |
Q35490056 | Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations |
Q37397658 | CHEK2*1100delC homozygosity in the Netherlands--prevalence and risk of breast and lung cancer |
Q50645287 | Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome. |
Q35889575 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. |
Q34493797 | Common low-penetrance risk variants associated with breast cancer in Polish women |
Q30478981 | Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study |
Q36927199 | Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral |
Q33985107 | Do alterations in mitochondrial DNA play a role in breast carcinogenesis? |
Q54642509 | Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene? |
Q42640946 | Effect of multiplicity, laterality, and age at onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study |
Q30360376 | Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms |
Q34865460 | Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study |
Q37004792 | Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer |
Q35477949 | Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population |
Q34938728 | Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families |
Q34426529 | Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles |
Q36243757 | Familial non-BRCA1/BRCA2-associated breast cancer |
Q54587377 | Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes. |
Q38041587 | Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application |
Q37156413 | Genetic susceptibility loci for breast cancer by estrogen receptor status |
Q41130542 | Genetic susceptibility to breast cancer |
Q34295620 | Genome-wide association study of circulating estradiol, testosterone, and sex hormone-binding globulin in postmenopausal women |
Q51691340 | Genome-wide linkage scan in Dutch hereditary non-BRCA1/2 breast cancer families identifies 9q21-22 as a putative breast cancer susceptibility locus. |
Q54249734 | Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas. |
Q45972889 | Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. |
Q44358800 | Germline mutations in RAD51C in Jewish high cancer risk families |
Q34425230 | Hereditary breast cancer: clinical, pathological and molecular characteristics |
Q86824997 | Heterozygous germline mutations in NBS1 among Korean patients with high-risk breast cancer negative for BRCA1/2 mutation |
Q35105646 | High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients. |
Q36041250 | Hypothesis: Activation of rapid signaling by environmental estrogens and epigenetic reprogramming in breast cancer |
Q34743854 | Identification of a breast cancer susceptibility locus at 4q31.22 using a genome-wide association study paradigm |
Q37670809 | Implications of single nucleotide polymorphisms in CD44 exon 2 for risk of breast cancer |
Q37378034 | Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model |
Q36925229 | Inherited and acquired alterations in development of breast cancer. |
Q36067806 | Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis. |
Q33483075 | Low-risk susceptibility alleles in 40 human breast cancer cell lines |
Q38153187 | Male breast cancer: genetics, epigenetics, and ethical aspects. |
Q38844679 | Management of women with a hereditary predisposition for breast cancer |
Q36602581 | Models of genetic susceptibility to breast cancer |
Q90413979 | Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management |
Q36623385 | Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein |
Q33258847 | Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families |
Q33348765 | Novel de novo BRCA2 mutation in a patient with a family history of breast cancer |
Q35939849 | Obesity is a significant risk factor for breast cancer in Arab women |
Q38843992 | Olaparib for the treatment of breast cancer. |
Q37925056 | Oral cancer in young non-habituè females: a report of four cases and review of the literature |
Q55110010 | Pathology of hereditary breast cancer. |
Q34023724 | Pattern response of dendritic cells in the tumor microenvironment and breast cancer |
Q50997123 | Platform comparisons for identification of breast cancers with a BRCA-like copy number profile. |
Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
Q33916899 | Psychosocial and behavioral impact of breast cancer risk assessed by testing for common risk variants: protocol of a prospective study |
Q51808027 | Psychosocial and ethical issues relating to genetic testing for BRCA1 and BRCA2 breast cancer susceptibility genes. |
Q58739875 | Rapid detection of copy number variations and point mutations in genes using a single workflow by ion semiconductor sequencing pipeline |
Q37373918 | Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer |
Q28743906 | Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study |
Q35962026 | Recognizing BRCA gene mutation risk subsequent to breast cancer diagnosis in southwestern Ontario |
Q35181094 | Review: mitochondrial defects in breast cancer |
Q36430753 | Risk prediction models for familial breast cancer |
Q54093040 | SYK expression level distinguishes control from BRCA1-mutated lymphocytes. |
Q50548721 | Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer. |
Q33395135 | Selecting a BRCA risk assessment model for use in a familial cancer clinic |
Q41387543 | Six low-penetrance SNPs for the estimation of breast cancer heritability: A family-based study in Caucasian Italian patients |
Q36611450 | TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer |
Q35180956 | The 'Pokemon' (ZBTB7) Gene: No Evidence of Association with Sporadic Breast Cancer. |
Q37665532 | The LSP1 rs3817198 T > C polymorphism contributes to increased breast cancer risk: a meta-analysis of twelve studies |
Q82987365 | The Mcs7 quantitative trait locus is associated with an increased susceptibility to mammary cancer in congenic rats and an allele-specific imbalance |
Q57272203 | The emerging landscape of breast cancer susceptibility |
Q28074414 | The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance |
Q35747645 | Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden |
Q50281677 | Unique CD44 intronic SNP is associated with tumor grade in breast cancer: a case control study and in silico analysis. |
Q34069483 | Unique SNP in CD44 intron 1 and its role in breast cancer development. |
Q30423128 | Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study |
Q33636005 | Variation in genes required for normal mitosis and risk of breast cancer |
Search more.